GUIDED THERAPEUTICS INC Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

GUIDED THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Statements in this report which express "belief," "anticipation" or "expectation," as well as other statements which are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or anticipated results, including those set forth under "Risk Factors" below and elsewhere in this report. Examples of these uncertainties and risks include, but are not limited to: · access to sufficient debt or equity capital to meet our operating and financial needs; · the effectiveness and ultimate market acceptance of our products; · whether our products in development will prove safe, feasible and effective; · whether and when we or any potential strategic partners will obtain approval from the U.S FDA and corresponding foreign agencies; · our need to achieve manufacturing scale-up in a timely manner, and our need to provide for the efficient manufacturing of sufficient quantities of our products; · the lack of immediate alternate sources of supply for some critical components of our products; · our patent and intellectual property position; · the need to fully develop the marketing, distribution, customer service and technical support and other functions critical to the success of our product lines; and · the dependence on potential strategic partners or outside investors for funding, development assistance, clinical trials, distribution and marketing of some of our products. The following discussion should be read in conjunction with our financial statements and notes thereto included elsewhere in this report. OVERVIEW ...
Click here to read the whole Article (external link)

GUIDED THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Show all filings for GUIDED THERAPEUTICS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for GUIDED THERAPEUTICS INC 10-Nov-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informa...
Click here to read the whole Article (external link)

Guided Therapeutics Non-Invasive Cervical Cancer Detection Device Trial Confirms Current Tests Miss Disease; Create High False Positive Rates

BOSTON--(BUSINESS WIRE)--Results of the FDA pivotal clinical trial for the LightTouchâ„¢ Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP - News), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI). In the new LightTouch study, conducted at six US clinics and with an enrollment of approximately 2,000 women, 32% of cervical precancers and cancers were missed by the current method of human papillomavirus (HPV) testing and colposcopy, while only 19% of biopsy samples indicated the presence of these diseases. Similarly,...
Click here to read the whole Article (external link)

GUIDED THERAPEUTICS INC Files SEC form 8-K, Other Events

Show all filings for GUIDED THERAPEUTICS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for GUIDED THERAPEUTICS INC 2-Nov-2009Other Events Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for t...
Click here to read the whole Article (external link)

Guided Therapeutics to Introduce New Cancer Detection Technology at Medica 2009

NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP - News) today announced plans to introduce its LightTouch™ non-invasive cancer detection technology at Medica 2009 in Düsseldorf, Germany November 18 - 20, 2009. GT will be showcasing the LightTouch Cervical Neoplasia Detection System in anticipation of a 2010 international launch. GT intends to meet with medical device distributors with gynecological market expertise, as well as government purchasing officials, in order to better understand the cervical cancer market structure in the various countries.The company is also looking to identify physicians who specialize in colposcopy and cervical disease management in the interest of establishing partnerships for multinational clinical studies involving the LightTouch.“We believe the LightTouch will significantly improve the standard of care in the area of cervical pre-cancer detection in a wide range of market settings,” said Mark L. Faupel, Ph.D., President and CEO of GT. “Our exper...
Click here to read the whole Article (external link)

GUIDED THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Show all filings for GUIDED THERAPEUTICS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for GUIDED THERAPEUTICS INC 8-Oct-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informa...
Click here to read the whole Article (external link)

Guided Therapeutics wins $2.5M grant

ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | view digital edition | ...
Click here to read the whole Article (external link)

National Cancer Institute Grants Guided Therapeutics, Inc. $2.5 Million to Commercialize Non-Invasive Cervical Cancer Detection Device

NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP - News) today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable. “This grant provides significant non-dilutive resources for us to begin manufacturing LightTouch devices and disposables for an international launch, as we simultaneously complete the U.S. Food and Drug Administration (FDA) pre-market approval (PMA) application process,” said Mark L. Faupe...
Click here to read the whole Article (external link)

GUIDED THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Def

Item 1.01. Entry Into a Material Definitive Agreement. On August 31, 2009, Guided Therapeutics, Inc. (the "Company") issued additional 13% Senior Secured Convertible Notes of the Company in the aggregate principal amount of approximately $3.5 million (the "New Notes"). The New Notes were issued pursuant to the Company's existing Amended and Restated Loan Agreement, dated March 1, 2007 ("2007 Loan Agreement"). The New Notes were principally sold to certain existing security holders of the Company. Prior to the issuance of the New Notes, there were approximately $4.5 million in aggregate principal amount of 13% Senior Secured Convertible Notes outstanding, which were issued previously pursuant to the 2007 Loan Agreement ("Existing 2007 Notes", and together with the New Notes, the "Senior Notes"). Accrued interest on the Existing 2007 Notes as of August 31, 2009, was approximately $1.5 million. The Senior Notes mature on March 1, 2010. Prior to any event of default, interest accrues on the Senior Notes at 13% per annum, and is due at maturity. The Senior Notes are senior secured obligations of the Company and are secured by (a) a first in priority lien on all of the Company's assets; (b) a guaranty by the Company's wholly owned subsidiary, InterScan Inc. ("InterScan"); (c) a lien on all of InterScan's assets; and (d) a pledge on all issued and outstanding stock of InterScan and another (inactive) wholly owned subsidiary of the Company. The New Notes are convertible, subject to certain adjustments, into approximately 5.4 million shares of the Company's Common Stock. The Existing 2007 Notes are convertible, subject to certain adjustments, into approximately 9.1 million shares of Common Stock. The principal amount and all accrued but unpaid interest of each Senior Note is convertible at the election of the holder thereof. In addition, the Senior Notes are automatically convertible into shares of Common Stock should the a...
Click here to read the whole Article (external link)